dc.contributor.author | Sadowska-Bartosz, Izabela | |
dc.contributor.author | Galiniak, Sabina | |
dc.contributor.author | Bartosz, Grzegorz | |
dc.contributor.author | Rachel, Marta | |
dc.date.accessioned | 2016-04-12T08:42:04Z | |
dc.date.available | 2016-04-12T08:42:04Z | |
dc.date.issued | 2014 | |
dc.identifier.issn | 1942-0900 | |
dc.identifier.uri | http://hdl.handle.net/11089/17780 | |
dc.description.abstract | Pseudomonas aeruginosa and Staphylococcus aureus cause chronic lung infection in cystic fibrosis (CF) patients, inducing chronic
oxidative stress. Several markers of plasma protein oxidative damage and glycoxidation and activities of erythrocyte antioxidant
enzymes have been compared in stable CF patients chronically infected with Pseudomonas aeruginosa (𝑛 = 12) and Staphylococcus
aureus (𝑛 = 10) in relation to healthy subjects (𝑛 = 11). Concentration of nitric oxide was also measured in the exhaled air from the
lower respiratory tract of patients with CF. Elevated glycophore (4.22 ± 0.91 and 4.19 ± 1.04 versus control 3.18 ± 0.53 fluorescence
units (FU)/mg protein; 𝑃 < 0.05) and carbonyl group levels (1.9 ± 0.64, 1.87 ± 0.45 versus control 0.94 ± 0.19 nmol/mg protein;
𝑃 < 0.05) as well as increased glutathione S-transferase activity (2.51 ± 0.88 and 2.57 ± 0.79 U/g Hb versus 0.77 ± 0.16 U/g Hb;
𝑃 < 0.05) were noted in Pseudomonas aeruginosa and Staphylococcus aureus infected CF. Kynurenine level (4.91 ± 1.22 versus 3.89
± 0.54 FU/mg protein; 𝑃 < 0.05) was elevated only in Staphylococcus aureus infected CF. These results confirm oxidative stress in
CF and demonstrate the usefulness of the glycophore level and protein carbonyl groups as markers of oxidative modifications of
plasma proteins in this disease | pl_PL |
dc.description.sponsorship | The study has been supported by the Polish Ministry of Science and Higher Education with an Iuventus Plus Grant IP2011047971 | pl_PL |
dc.language.iso | en | pl_PL |
dc.publisher | Hindawi Publishing Corporation | pl_PL |
dc.relation.ispartofseries | Oxidative Medicine and Cellular Longevity;2014 | |
dc.rights | Uznanie autorstwa 3.0 Polska | * |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/pl/ | * |
dc.title | Oxidative Modification of Proteins in Pediatric Cystic Fibrosis with Bacterial Infections | pl_PL |
dc.type | Article | pl_PL |
dc.page.number | 1-10 | pl_PL |
dc.contributor.authorAffiliation | University of Rzeszów, Department of Biochemistry and Cell Biology | pl_PL |
dc.contributor.authorAffiliation | University of Łódź, Department of Molecular Biophysics | pl_PL |
dc.contributor.authorAffiliation | University of Rzeszów, Faculty of Medicine | pl_PL |
dc.identifier.eissn | 1942-0994 | |
dc.references | J. B. Lyczak, C. L. Cannon, and G. B. Pier, “Lung infections associated with cystic fibrosis,” Clinical Microbiology Reviews, vol. 15, no. 2, pp. 194–222, 2002 | pl_PL |
dc.references | J. F. Chmiel, M. W. Konstan, and J. S. Elborn, “Antibiotic and anti-inflammatory therapies for cystic fibrosis,” Cold Spring Harbor Perspectives in Medicine, vol. 3, no. 10, Article ID a009779, 2013 | pl_PL |
dc.references | P. J. Dubin and J. K. Kolls, “IL-23 mediates inflammatory responses to mucoid Pseudomonas aeruginosa lung infection in mice,” American Journal of Physiology, vol. 292, no. 2, pp. L519–L528, 2007 | pl_PL |
dc.references | D. E. Geller, “Aerosol antibiotics in cystic fibrosis,” Respiratory Care, vol. 54, no. 5, pp. 658–669, 2009 | pl_PL |
dc.references | L. R. Usher, R. A. Lawson, I. Geary et al., “Induction of neutrophil apoptosis by the Pseudomonas aeruginosa exotoxin pyocyanin: a potential mechanism of persistent infection,” Journal of Immunology, vol. 168, no. 4, pp. 1861–1868, 2002 | pl_PL |
dc.references | J. K. Wong, S. C. Ranganathan, and E. Hart, “Staphylococcus aureus in early cystic fibrosis lung disease,” Pediatric Pulmonology, 2013 | pl_PL |
dc.references | M. Rottner, S. Tual-Chalot, H. A. Mostefai, R. Andriantsitohaina, J.-M. Freyssinet, and M. C. Martínez, “Increased oxidative stress induces apoptosis in human cystic fibrosis cells,” PLoS ONE, vol. 6, no. 9, Article ID e24880, 2011 | pl_PL |
dc.references | A. Lezo, F. Biasi, P. Massarenti, et al., “Oxidative stress in stable cystic fibrosis patients: do we need higher antioxidant plasma levels?” Journal of Cystic Fibrosis, vol. 12, pp. 35–41, 2013 | pl_PL |
dc.references | E. I. Back, C. Frindt, D. Nohr et al., “Antioxidant deficiency in cystic fibrosis: when is the right time to take action?” American Journal of Clinical Nutrition, vol. 80, no. 2, pp. 374–384, 2004 | pl_PL |
dc.references | I. Sadowska-Woda, M. Rachel, J. Pazdan, E. Bieszczad-Bedrejczuk, and K. Pawliszak, “Nutritional supplement attenuates selected oxidative stress markers in pediatric patients with cystic fibrosis,” Nutrition Research, vol. 31, no. 7, pp. 509–518, 2011 | pl_PL |
dc.references | R. K. Brown and F. J. Kelly, “Evidence for increased oxidative damage in patients with cystic fibrosis,” Pediatric Research, vol. 36, no. 4, pp. 487–493, 1994 | pl_PL |
dc.references | M. J. Davies, “The oxidative environment and protein damage,” Biochimica et Biophysica Acta, vol. 1703, no. 2, pp. 93–109, 2005 | pl_PL |
dc.references | B. Arif, J. M. Ashraf, A. J. Moinuddin, et al., “Structural and immunological characterization of Amadori-rich human serum albumin: role in diabetes mellitus,” Archives of Biochemistry and Biophysics, vol. 522, pp. 17–25, 2012 | pl_PL |
dc.references | K. Marta, Z. Tomáš, P. Petr et al., “Advanced glycation end-products in patients with chronic alcohol misuse,” Alcohol and Alcoholism, vol. 39, no. 4, pp. 316–320, 2004 | pl_PL |
dc.references | V. Witko-Sarsat, M. Friedlander, C. Capeillère-Blandin et al., “Advanced oxidation protein products as a novel marker of oxidative stress in uremia,” Kidney International, vol. 49, no. 5, pp. 1304–1313, 1996 | pl_PL |
dc.references | A. Robaszkiewicz, G. Bartosz, and M. Soszyński, “N-chloroamino acids cause oxidative protein modifications in the erythrocyte membrane,” Mechanisms of Ageing and Development, vol. 129, no. 10, pp. 572–579, 2008 | pl_PL |
dc.references | M. Valko, D. Leibfritz, J. Moncol, M. T. D. Cronin, M. Mazur, and J. Telser, “Free radicals and antioxidants in normal physiological functions and human disease,” International Journal of Biochemistry and Cell Biology, vol. 39, no. 1, pp. 44–84, 2007 | pl_PL |
dc.references | W. H. Habig, M. J. Pabst, and W. B. Jakoby, “Glutathione S transferases. The first enzymatic step in mercapturic acid formation,” Journal of Biological Chemistry, vol. 249, no. 22, pp. 7130–7139, 1974 | pl_PL |
dc.references | R. A. Dweik, P. B. Boggs, S. C. Erzurum et al., “An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications,” American Journal of Respiratory and Critical Care Medicine, vol. 184, no. 5, pp. 602–615, 2011 | pl_PL |
dc.references | NCCLS, “Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically,” Approved Standard, 6th Edition. NCCLS document M7-A6, NCCLS | pl_PL |
dc.references | A. J. Scott-Thomas, M. Syhre, P. K. Pattemore et al., “2-Aminoacetophenone as a potential breath biomarker for Pseudomonas aeruginosa in the cystic fibrosis lung,” BMC Pulmonary Medicine, vol. 10, article 56, 2010 | pl_PL |
dc.references | G. A. Tramper-Stranders, T. F. W. Wolfs, A. Fleer, J. L. L. Kimpen, and C. K. Van Der Ent, “Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function,” Pediatric Infectious Disease Journal, vol. 26, no. 1, pp. 8–12, 2007 | pl_PL |
dc.references | A. Z. Reznick and L. Packer, “Oxidative damage to proteins: spectrophotometric method for carbonyl assay,” Methods in Enzymology, vol. 233, pp. 357–363, 1994 | pl_PL |
dc.references | T. Henle, R. Deppisch, W. Beck, O. Hergesell, G. M. Hänsch, and E. Ritz, “Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds,” Nephrology Dialysis Transplantation, vol. 14, no. 8, pp. 1968–1975, 1999 | pl_PL |
dc.references | G. Münch, R. Keis, A. Weßels et al., “Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA1,” European Journal of Clinical Chemistry and Clinical Biochemistry, vol. 35, no. 9, pp. 669–677, 1997 | pl_PL |
dc.references | O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall, “Protein measurement with the Folin phenol reagent,” The Journal of Biological Chemistry, vol. 193, no. 1, pp. 265–275, 1951 | pl_PL |
dc.references | R. N. Johnson, P. A. Metcalf, and J. R. Baker, “Fructosamine: a new approach to the estimation of serum glycosylprotein. An index of diabetic control,” Clinica Chimica Acta, vol. 127, no. 1, pp. 87–95, 1983 | pl_PL |
dc.references | R. Mironova, T. Niwa, Y. Handzhiyski, A. Sredovska, and I. Ivanov, “Evidence for non-enzymatic glycosylation of Escherichia coli chromosomal DNA,” Molecular Microbiology, vol. 55, no. 6, pp. 1801–1811, 2005 | pl_PL |
dc.references | A. T. Diplock, M. C. R. Symons, and C. A. Rice-Evans, Techniques in Free Radical Research, Elsevier Science, Tokyo, Japan, 1991 | pl_PL |
dc.references | G. L. Ellman, “Tissue sulfhydryl groups,” Archives of Biochemistry and Biophysics, vol. 82, no. 1, pp. 70–77, 1959 | pl_PL |
dc.references | H. Aebi, “Catalase in vitro,” Methods in Enzymology, vol. 105, pp. 121–126, 1984 | pl_PL |
dc.references | S. Marklund and G. Marklund, “Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase,” European Journal of Biochemistry, vol. 47, no. 3, pp. 469–474, 1974 | pl_PL |
dc.references | D. L. Drabkin, “Spectrophotometric studies; the crystallographic and optical properties of the hemoglobin of man in comparison with those of other species,” Journal of Biological Chemistry, vol. 164, pp. 703–723, 1946 | pl_PL |
dc.references | P. Ø. Jensen, J. Lykkesfeldt, T. Bjarnsholt, H. P. Hougen, N. Høiby, and O. Ciofu, “Poor antioxidant status exacerbates oxidative stress and inflammatory response to Pseudomonas aeruginosa lung infection in guinea pigs,” Basic and Clinical Pharmacology and Toxicology, vol. 110, no. 4, pp. 353–358, 2012 | pl_PL |
dc.references | O. Ciofu, B. Riis, T. Pressler, H. E. Poulsen, and N. Høiby, “Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation,” Antimicrobial Agents and Chemotherapy, vol. 49, no. 6, pp. 2276–2282, 2005 | pl_PL |
dc.references | B. M. Winklhofer-Roob, “Oxygen free radicals and antioxidants in cystic fibrosis: the concept of an oxidant-antioxidant imbalance,” Acta Paediatrica, vol. 83, no. 395, pp. 49–57, 1994 | pl_PL |
dc.references | F. Galli, A. Battistoni, R. Gambari et al., “Oxidative stress and antioxidant therapy in cystic fibrosis,” Biochimica et Biophysica Acta, vol. 1822, no. 5, pp. 690–713, 2012 | pl_PL |
dc.references | R. K. Brown, H. Wyatt, J. F. Price, and F. J. Kelly, “Pulmonary dysfunction in cystic fibrosis is associated with oxidative stress,” European Respiratory Journal, vol. 9, no. 2, pp. 334–339, 1996 | pl_PL |
dc.references | C. C. Winterbourn, M. J. D. Bonham, H. Buss, F. M. Abu-Zidan, and J. A. Windsor, “Elevated protein carbonyls as plasma markers of oxidative stress in acute pancreatitis,” Pancreatology, vol. 3, no. 5, pp. 375–382, 2003 | pl_PL |
dc.references | M.-N. Feuillet-Fieux, T. Nguyen-Khoa, M.-A. Loriot et al., “Glutathione S-transferases related to P. aeruginosa lung infection in cystic fibrosis children: preliminary study,” Clinical Biochemistry, vol. 42, no. 1-2, pp. 57–63, 2009 | pl_PL |
dc.references | T. Satoh, S. R. McKercher, and S. A. Lipton, “Nrf2/ARE-mediated antioxidant actions of pro-electrophilic drugs,” Free Radical Biology and Medicine, vol. 65, pp. 645–657, 2013 | pl_PL |
dc.references | Y. Xu, C. Duan, Z. Kuang, et al., “Pseudomonas aeruginosa pyocyanin activates Nrf2-ARE-mediated transcriptional response via the ROS-EGFR-PI3K-AKT/MEK-ERK MAP kinase signaling in pulmonary epithelial cells,” PLoS ONE, vol. 8, Article ID e72528, 2013 | pl_PL |
dc.references | R. K. Michl, J. Hentschel, C. Fischer, et al., “Reduced nasal nitric oxide production in cystic fibrosis patients with elevated systemic inflammation markers,” PLoS ONE, vol. 8, Article ID e79141, 2013 | pl_PL |
dc.references | L. Fila, J. Chladek, M. Maly, et al., “Nitrites and nitrates in exhaled breath condensate in cystic fibrosis: relation to clinical parameters,” Bratislavske Lekarske Listy, vol. 114, pp. 503–507, 2013 | pl_PL |
dc.references | S. R. Thomas, S. A. Kharitonov, S. F. Scott, M. E. Hodson, and P. J. Barnes, “Nasal and exhaled nitric oxide is reduced in adult patients with cystic fibrosis and does not correlate with cystic fibrosis genotype,” Chest, vol. 117, no. 4, pp. 1085–1089, 2000 | pl_PL |
dc.references | C. M. Robroeks, P. P. R. Rosias, D. van Vliet et al., “Biomarkers in exhaled breath condensate indicate presence and severity of cystic fibrosis in children,” Pediatric Allergy and Immunology, vol. 19, no. 7, pp. 652–659, 2008 | pl_PL |
dc.references | K. M. de Winter-de Groot, S. van Haren Noman, L. Speleman, et al., “Nasal nitric oxide levels and nasal polyposis in children and adolescents with cystic fibrosis,” JAMA Otolaryngology, vol. 139, pp. 931–936, 2013 | pl_PL |
dc.references | M. Zhou, Y. Liu, and Y. Duan, “Breath biomarkers in diagnosis of pulmonary diseases,” Clinica Chimica Acta, vol. 413, pp. 1770–1780, 2012 | pl_PL |
dc.references | L. P. Ho, J. A. Innes, and A. R. Greening, “Exhaled nitric oxide is not elevated in the inflammatory airways diseases of cystic fibrosis and bronchiectasis,” European Respiratory Journal, vol. 12, no. 6, pp. 1290–1294, 1998 | pl_PL |
dc.references | W. T. Walker, A. Liew, A. Harris, et al., “Upper and lower airway nitric oxide levels in primary ciliary dyskinesia, cystic fibrosis and asthma,” Respiratory Medicine, vol. 107, pp. 380–386, 2013 | pl_PL |
dc.contributor.authorEmail | isadowska@poczta.fm | pl_PL |
dc.identifier.doi | 10.1155/2014/389629 | |